Logo image of MYNZ

MAINZ BIOMED NV (MYNZ) Stock News

NASDAQ:MYNZ - Nasdaq - NL0015000LC2 - Common Stock - Currency: USD

5.07  -0.16 (-3.06%)

After market: 5.1 +0.03 (+0.59%)

MYNZ Latest News, Press Relases and Analysis

News Image
19 hours ago - Mainz BioMed NV

Colorectal Cancer Awareness Month: Mainz Biomed Advocates for a Shift from Screening to Prevention

Colorectal Cancer Awareness Month: Mainz Biomed Advocates for a Shift from Screening to Prevention...

News Image
12 days ago - Mainz BioMed NV

Mainz Biomed Expands into Switzerland with labor team w

Mainz Biomed Expands into Switzerland with labor team w...

News Image
12 days ago - Mainz BioMed NV

Mainz Biomed Expands into Switzerland with labor team w

Partnership to Launch DNA-Based Colorectal Cancer Screening Test

News Image
3 months ago - Mainz BioMed NV

Mainz Biomed Announces Closing of $8.0 Million Follow-On Offering

Mainz Biomed Announces Closing of $8.0 Million Follow-On Offering ...

News Image
3 months ago - Mainz BioMed NV

Mainz Biomed Announces Stock Split

Mainz Biomed Announces Stock Split...

News Image
21 days ago - Mainz BioMed NV

Mainz Biomed and GANZIMMUN Announce Launch of Enhanced ColoAlert Colorectal Cancer Screening Ahead of Awareness Month

Mainz Biomed and GANZIMMUN Announce Launch of Enhanced ColoAlert Colorectal Cancer Screening Ahead of Awareness Month...

News Image
21 days ago - Mainz BioMed NV

Mainz Biomed and GANZIMMUN Announce Launch of Enhanced ColoAlert Colorectal Cancer Screening Ahead of Awareness Month

Updated Screening Guidelines Ensure Broader Access to Colorectal Cancer Screening in Germany

News Image
a month ago - Mainz BioMed NV

Mainz Biomed N.V. Regains Compliance with Nasdaq Capital Market Listing Requirements

Mainz Biomed N.V. Regains Compliance with Nasdaq Capital Market Listing Requirements...

News Image
a month ago - Mainz BioMed NV

Mainz Biomed Initiates U.S. Clinical Study to Evaluate Performance of Next Generation Test on Advanced Adenomas over Large Patient Population

Mainz Biomed Initiates U.S. Clinical Study to Evaluate Performance of Next Generation Test on Advanced Adenomas over Large Patient Population...

News Image
2 months ago - Mainz BioMed NV

Mainz Biomed Forms Agreement with Quest Diagnostics to Provide Clinical Trials Laboratory Services for Colorectal Cancer Screening Test

Mainz Biomed Forms Agreement with Quest Diagnostics to Provide Clinical Trials Laboratory Services for Colorectal Cancer Screening Test...

News Image
2 months ago - Mainz BioMed NV

Mainz Biomed Forms Agreement with Quest Diagnostics to Provide Clinical Trials Laboratory Services for Colorectal Cancer Screening Test

Quest to Support Mainz Biomed’s ReconAAsense FDA Study and Has Option to Commercialize Test Kit Assuming FDA Approval

Mentions: DGX

News Image
3 months ago - Mainz BioMed NV

Mainz Biomed Announces Pricing of $8.0 Million Follow-On Offering Priced at-the-Market Under Nasdaq Rules

Mainz Biomed Announces Pricing of $8.0 Million Follow-On Offering Priced at-the-Market Under Nasdaq Rules...

News Image
3 months ago - Mainz BioMed NV

Mainz Biomed Announces Stock Split

News Image
4 months ago - Mainz BioMed NV

Mainz Biomed Reports Mid-Year 2024 Financial Results and Provides Corporate Update

Mainz Biomed Reports Mid-Year 2024 Financial Results and Provides Corporate Update...

News Image
5 months ago - Mainz BioMed NV

Mainz Biomed Reports Increased Demand for Enhanced ColoAlert, Existing Partners to Transition to New Version

Mainz Biomed Reports Increased Demand for Enhanced ColoAlert, Existing Partners to Transition to New Version; GANZIMMUN Diagnostics to Feature ColoAlert ...

News Image
5 months ago - Mainz BioMed NV

Mainz Biomed Reports Increased Demand for Enhanced ColoAlert, Existing Partners to Transition to New Version

GANZIMMUN Diagnostics to Feature ColoAlert at the 57th Medizinische Woche Baden-Baden

News Image
5 months ago - Mainz BioMed NV

Mainz Biomed Publishes CEO Statement; CEO Guido Baechler Eyes Major Growth and U.S. FDA Trials in 2025

Mainz Biomed Publishes CEO Statement; CEO Guido Baechler Eyes Major Growth and U.S. FDA Trials in 2025...

News Image
6 months ago - Mainz BioMed NV

Mainz Biomed Announces Petra Smeltzer Starke to Join Company as Brand Ambassador

Mainz Biomed Announces Petra Smeltzer Starke to Join Company as Brand Ambassador...

News Image
6 months ago - Mainz BioMed NV

Mainz Biomed Announces Petra Smeltzer Starke to Join Company as Brand Ambassador

Strategic Alliance with Former White House Senior Adviser to Focus on Awareness of Mainz Biomed’s Products and the Importance of Early Detection